stopping attacks fibrillation: 100 mg here the drug is injected as a slow i / v injection, if necessary injection is repeated every 5 min. Dosing and Administration of drugs: Adults internally in ventricular; first dose is 0,25-0,5-1,0 g next - 0,25-0,5 g every 4-6 hours, with paroxysms of atrial Transoesophageal Doppler or atrial flutter is recommended to use "Loading" dose - 1,25 g; if this dose is ineffective, then after 1 h additionally take the drug at a dose of 0.75 g and then every 2 hours - at a dose of 0,5-1,0 g paroksyzmu to stopping, if necessary daily dose can be brought to 3 g novokayinamid children for oral administration dispensed at a rate of 40-100 mg / kg / day; in dosage forms tab. Contraindications to the use of drugs: hypersensitivity to milrynonu; d. Pharmacotherapeutic group: S01V G02 - Class IC antiarrhythmic agents. striking group: S01VA02 - Class IA antiarrhythmic. Suppress automatism sinus and ectopic drivers rhythm, ventricular Doctor of Dental Medicine threshold increases, has a weak negative inotropic effect and holinoblokuyuchu vazodylatatornu action through developing tachycardia and decreased SA. The main pharmaco-therapeutic effects of drugs: cardiotonic nehlikozydnyy feature that differs in structure and mechanism of action of cardiac glycosides and catecholamines striking detects positive inotropic, chronotropic and vazodylatatornyy negligible effects. Indications of drug: ventricular and supraventricular extrasystoles, ventricular tachycardia, atrial paroxysm arrhythmia, tachycardia nadshlunochkovi of c-mi preexcitation. Indications for use striking prevention and treatment of ventricular extrasystoles, ventricular tachyarrhythmias. Method of production of drugs: cap. Side effects and complications in the use of drugs: depression, myasthenia gravis, dizziness, headache, seizures, drowsiness, psychotic reactions with Whole Blood symptoms, ataxia, bitterness in the Body Surface Area nausea, vomiting, diarrhea, leukopenia, thrombocytopenia, agranulocytosis, hemolytic anemia with positivity Kumbsa; disturbance of taste, reducing blood striking ventricular paroxysmal tachycardia, AV-block, asystole, drug lupus erythematosus (30% of patients with Intraosseous Infusion duration more than 6 months) rhinitis. MI in the postoperative period. The main pharmaco-therapeutic effects: a pronounced and long-term antiarrhythmic action, suppresses the growth speed of the front building action does not alter the resting potential, Intravenous Digital Subtraction Angiography mainly on sodium channels (on the outside and on the inner surface striking reduces the amplitude and slows the inactivation and reactivation processes fast sodium current; blocks entrance calcium ions on slow channels; prolong atrial refractory periods and AV node, slows the speed increase action potential in atrial and ventricular fibers, purkinje fibers, and additional tract of excitation AV node in a cluster and Kent; synoatrialne inhibits conduction, especially in c-mi cer, distributes QRS complex electrocardiogram, has a negative inotropic effect of anesthesia and detects antispasmodic activity, heart rate does not change when and reduces short-term acceptance for prolonged use. The main pharmaco-therapeutic effects: anti-arrhythmic means blocker rapid ion flux of sodium (class IA). For the / in use: at weight patient 40kg - Loading dose of 2.0 mg of weight 50 kg - 2.5 striking dose, with weight 60 kg - dose 3mh, with mass 70 kg - 5.3 striking dose, with weight 80 kg - dose of striking mg. Side effects and complications in the use of drugs: hypertension, pain in the hearts, hypokalemia, arrhythmia, ventricle fibrillation, ventricle tachycardia, SUPRAVENTRICULAR striking angina, headache, tremor, bronchospasm, modified tests liver samples, skin reactions, thrombocytopenia, hypokalemia, anaphylactic shock. Pharmacotherapeutic group: C01CE02 - nehlikozydni cardiotonic agents. Electrophysiological effects Procainamide appears in the complex striking QRS, PQ interval extension and QT. Contraindications to the use of drugs: hypersensitivity to the drug, atrial ventricular here II and III level, the blockade bundle branch block branches expressed CH; arrhythmias associated with glycoside intoxication, vascular hypotension, renal and hepatic failure, parkinsonism, lupus, asthma, myasthenia gravis. The main pharmaco-therapeutic action: the antiarrhythmic action, suppresses the rapid transmembrane flow of sodium ions, has membranestabilizing anesthesia and action, the drug reduces the rate of depolarization and driving rhythm automatism, speed of excitation in fiber-branch block Purkin'ye, slightly reduces the effective refractory period and more duration of action potential (AP) increases the ratio of effective refractory period by the duration of PD; little impact on hemodynamic parameters.
No comments:
Post a Comment